Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

NSCLC, metastatic

5639 - Randomized double blind phase IIb trial in advanced NSCLC patients who did not progress after first line platinum based chemotherapy : Vx-001, a therapeutic cancer vaccine, vs placebo as maintenance therapy.

Date

10 Sep 2017

Session

NSCLC, metastatic

Presenters

Cesare Gridelli

Citation

Annals of Oncology (2017) 28 (suppl_5): v605-v649. 10.1093/annonc/mdx440

Authors

C. Gridelli1, T. Ciuleanu2, M. Domine Gomez3, A. Szczesna4, I. Bover5, M. Cobo Dols6, N. Kentepozidis7, S. Viteri8, C. Manegold9, D. Khayat10, J. Douillard11, K. Kosmatopoulos12, V. Georgoulias13

Author affiliations

  • 1 Oncology, S.G. Moscati Hospital, 83100 - Avellino/IT
  • 2 Medical Oncology, The Oncology Institute Prof. Dr. Ion Chiricuta, Cluj-Napoca/RO
  • 3 Oncology, Fundación Jiménez Díaz, Madrid/ES
  • 4 Medical Oncology, Mazowieckie Centrum, Otwock/PL
  • 5 Medical Oncology, Grupo Español de Investigación en Cáncer de Ovario (GEICO) and Hospital Son Llàtzer, Palma de Mallorca/ES
  • 6 Medical Oncology, Hospital Regional Universitario de Malaga, Malaga/ES
  • 7 Medical Oncology, 251 Hellenic Airforce General Hospital, 115 25 - Athens/GR
  • 8 Oncology Department, Dexeus University Hospital-QuironSalud Group, Dr Rosell Oncology Institute, 80280 - Barcelona/ES
  • 9 Chirurgische Klinik, Universitätsklinikum Mannheim, 68167 - Mannheim/DE
  • 10 Medical Oncology, Groupe Hospitalier Pitié Salpetriere, 75651 - Paris/FR
  • 11 Department Of Medical Oncology, Institut de Cancérologie de l’Ouest (ICO) René Gauducheau, Nantes/FR
  • 12 Vaxon Biotech, Vaxon Biotech, 75015 - Paris/FR
  • 13 Medical Oncology, University Hospital of Heraklion, 712 01 - Heraklion/GR
More

Resources

Abstract 5639

Background

Vx-001 is a a therapeutic cancer vaccine with TERT (telomerase reverse transcriptase) antigen as target.

Methods

We tested the Vx-001 vaccine as maintenance therapy in a randomized double blind phase IIb trial in advanced NSCLC patients who did not progress after first line platinum based chemotherapy. Enrolled patients should be HLA-A 0201 positive and their tumor should express TERT. Overall survival (OS) was the primary endpoint of the study.

Results

1407 patients were screened and 221 were randomized. 190 patients (101 placebo and 89 Vx-001 treated) were analysed with no statistically significant in terms of OS beetwen arms. Interestingly there was a strong correlation between vaccine induced immune response and clinical outcome. OS was much longer in the 29% of patients who developed a Vx-001 specific immune response (21.3 months for immune responders vs 13.4 months for non-immune responders p = 0.004). 27% of enrolled patients had a natural immunity against several universal tumor antigens detected at baseline before vaccination suggesting that these patients should have strongly immunogenic tumors. Analysis of OS in this patient population with immunogenic tumors did not show any benefit in Vx-001 treated patients. Similar analysis of patients without natural immunity showed in Vx-001 arm a not statistically significant increase in OS (8.6 months vs 13.2 months, p = 0.27) suggesting that Vx-001 might be efficient in patients with non-immunogenic tumors. Since tumor immunogenicity is known to be associated to patients smoking status, a further analysis was focused according smoking habits. Very interestingly never smokers patients without natural immunity had a much longer OS when their were treated with Vx-001 as compared to placebo (8.6 vs 16.2 months HR = 0.20, p = 0.0008). This effects remained strong if we focused never smokers and former smokers who smoked for a short periode (less than 25 years). In this population OS in the Vx-001 arm was 20.7 months while in the placebo arm was 7.9 months (HR = 0.29, p = 0.0007).

Conclusions

These results suggest that Vx-001 might be efficient in patients without natural immunity and particularly in never smokers.

Clinical trial identification

NCT01935154, 26/08/2013

Legal entity responsible for the study

Vaxon Biotech

Funding

Vaxon Biotech

Disclosure

C. Gridelli: Honoraria as advisory board member for Vaxon Biotech. S. Viteri: Consulting (Boehringer Ingelheim, Clovis Oncology, Idea Pharma, Novartis, Promega Biotech Ibérica, Roche, Targovax). Research funding (AbbVie, Ariad, Astex, AstraZeneca/MedImmune, Boehringer Ingelheim, Clovis Oncology, CytRx, Daiichi Sankyo, GSK, Hanmi, Incyte, Merck KGaA, Novartis, Pfizer, Puma, Roche, Servier, Vaxon). C. Manegold: Travel support from Vaxon. D. Khayat: Consultant or advisory relationship to disclosure: Genomic Health France, Atlantic Sante, Celtic Biotech, Tolabo Radiochir. Stock or other ownership interest: Agenus Inc. J-Y. Douillard: Honoraria as advisory board member for Vaxon Biothec. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings